Supriya Lifescience Limited has scheduled a virtual interaction with analysts and institutional investors on June 12, 2026, to discuss its business performance and strategy. The meeting, part of the Choice Institutional Equities Virtual Investor Conference, will take place from 10:00 AM to 11:00 AM. This engagement allows the company to provide updates directly to the investment community, potentially influencing market perception and shareholder value.

The disclosure was made in compliance with Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. The company confirmed that the investor presentation has been made available on its official website and has been submitted to the stock exchanges for public access.

Prachi Sathe, Company Secretary & Compliance Officer, signed the regulatory filing on June 9, 2026. The communication addressed BSE Limited and the National Stock Exchange of India Limited, detailing the schedule for the upcoming group meeting.

The company noted that the scheduled date is subject to change due to exigencies on the part of the company or the participating analysts and investors. Stakeholders can access the detailed presentation through the company's official web portal.

Supriya Lifescience Limited reported an 11.3% year-on-year increase in net profit to ₹2,091.2 million for the year ended March 31, 2026, driven by robust revenue growth and operational efficiency. Revenue from operations rose 18.9% to ₹8,278.7 million, while EBITDA grew 12.8% to ₹2,940.5 million. For the quarter ended March 31, 2026, net profit surged 47.4% to ₹742.3 million, and revenue increased 50.2% to ₹2,765.3 million. The Board of Directors recommended a final dividend of Re. 1.00 per equity share, subject to shareholder approval.

FY26 Financial Performance

The company recorded growth across key financial metrics for the full year. The following table summarises the audited results for FY26 compared to FY25:

Q4 Performance

In the fourth quarter of FY26, the company reported a net profit of ₹742.3 million, compared to ₹503.7 million in Q4FY25. Revenue for Q4FY26 was ₹2,765.3 million, up from ₹1,841.1 million in the corresponding period of the previous year. EBITDA for the quarter stood at ₹976.2 million with a margin of 35.3%, compared to a margin of 36.7% in the prior year. Profit before tax (PBT) for the quarter increased 43.8% to ₹921.3 million.

Segment and Operational Details

The anesthetic segment continued to be the primary growth driver during FY26, contributing 54% of total revenues compared to 49% in FY25, while the vitamins segment contribution increased to 12% from 11%. Europe remained the largest market, contributing 40% of FY26 revenues, followed by Asia at 33% and LATAM at 20%. Export contribution remained strong at approximately 82% of FY26 revenues.

Capacity utilisation improved to 74% in FY26 from 70% in FY25, supported by the ramp-up of Module E at the Lote facility. The company commercialised its Liquid Anesthetic product and witnessed encouraging traction in newly launched products across the cardiovascular and ADHD segments. The Ambernath formulation facility commissioned five finished dosage manufacturing lines and continues to progress on validation and dossier submission activities.

Dividend Declaration

The Board of Directors, at its meeting held on May 27, 2026, recommended a final dividend of Re. 1.00 per equity share, equivalent to 50% on the face value of ₹2 each. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting.

Management Commentary and Outlook

During the earnings call held on May 28, 2026, management highlighted that the Lote facility received a USFDA Establishment Inspection Report (EIR) with a Voluntary Action Indicated classification following a surprise inspection in February 2026. The company reiterated its guidance for FY27, targeting approximately 20% annual revenue growth and EBITDA margins between 33% and 35%. Management stated the trajectory towards the ₹1,000 crore revenue milestone by FY27 remains on track, underpinned by a robust pipeline and planned launches of 3 to 4 products annually. The company secured all clearances for the Patalganga land, with Phase 1 groundbreaking expected in FY27 and a total capex of around ₹200 crore earmarked for the facility.